These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 27088384)

  • 41. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.
    Ruggeri A; Labopin M; Sanz G; Piemontese S; Arcese W; Bacigalupo A; Blaise D; Bosi A; Huang H; Karakasis D; Koc Y; Michallet M; Picardi A; Sanz J; Santarone S; Sengelov H; Sierra J; Vincent L; Volt F; Nagler A; Gluckman E; Ciceri F; Rocha V; Mohty M; ;
    Leukemia; 2015 Sep; 29(9):1891-900. PubMed ID: 25882700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.
    DeFilipp Z; Purcell M; Harris WA; Chandra DJ; Gleason C; Wrammert J; Sarantopoulos S; Waller EK
    Bone Marrow Transplant; 2016 Apr; 51(4):607-9. PubMed ID: 26642338
    [No Abstract]   [Full Text] [Related]  

  • 43. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?
    Papalexandri A; Karypidou M; Stalika E; Kotta K; Touloumenidou T; Zerva P; Paleta A; Mallouri D; Batsis I; Sakellari I; Kotsianidis I; Anagnostopoulos A; Hadzidimitriou A; Margaritis D; Stamatopoulos K
    Leuk Lymphoma; 2019 Jul; 60(7):1685-1692. PubMed ID: 30652530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
    Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D
    Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
    Pusic I; Pavletic SZ; Kessinger A; Tarantolo SR; Bishop MR
    Bone Marrow Transplant; 2002 Apr; 29(8):709-10. PubMed ID: 12180118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
    Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
    Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Graft-versus-host disease versus graft-versus-leukemia.
    Negrin RS
    Hematology Am Soc Hematol Educ Program; 2015; 2015():225-30. PubMed ID: 26637726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Uzunel M; Sairafi D; Remberger M; Mattsson J; Uhlin M
    Stem Cells Dev; 2014 Jul; 23(14):1559-67. PubMed ID: 24617310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [GVHD and GVL].
    Teshima T
    Rinsho Ketsueki; 2009 Oct; 50(10):1407-19. PubMed ID: 19915349
    [No Abstract]   [Full Text] [Related]  

  • 53. Fatal GVHD demonstrating an involvement of respiratory muscle following donor leukocyte transfusion (DLT).
    Oshima Y; Takahashi S; Nagayama H; Nishiwaki K; Kobayashi Y; Tojo A; Okamoto S; Tani K; Ozawa K; Wakabayashi T; Sato N; Kobayashi S; Nakamura K; Ohya Y; Nukina N; Kanazawa I; Asano S
    Bone Marrow Transplant; 1997 Apr; 19(7):737-40. PubMed ID: 9156252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute graft-versus-host-disease in acute myeloid leukemia: Clinicopathological correlation based on autopsy findings.
    Sharma P; Jandial A; Keisham A; Rohilla M; Varma N; Malhotra P; Radotra B
    Indian J Pathol Microbiol; 2021; 64(4):752-758. PubMed ID: 34673597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Graft versus host disease localized to striae distensae: An example of locus minoris resistentiae.
    Bishnoi A; Lad D; Ashraf R; Banerjee N; Saikia UN; Vinay K
    Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):555-557. PubMed ID: 33871201
    [No Abstract]   [Full Text] [Related]  

  • 60. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy.
    Fedele R; Cuzzola M; Irrera G; Pontari A; D'Ascola DG; Oliva EN; Martino M
    Leuk Lymphoma; 2016; 57(4):969-72. PubMed ID: 26308385
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.